Question 35902 — maternity health insurance

Summary

Mr. Mustapha Laabid draws the attention of the Minister of Solidarity and Health to the reimbursement by health insurance of medications based on anti-CGRP monoclonal antibodies whose antimigraine action has been recognized. Aimovig (erenumab) from the Novartis laboratory has had marketing authorization since 2019. Emgality (galcanezumab) from the Lilly laboratory and Ajovy (fremanezumab) obtained marketing authorization in June 2020. Reimbursement of these drugs is supported in many European countries. This is particularly the case in Spain, Belgium, Germany, Italy and Slovakia... However, their cost is around between 400 and 600 euros per month. Migraine is classified by the World Health Organization among the twenty diseases with the greatest societal impact and even rises to ninth place if only the female population is considered. In France, according to the French federation of neurology, nearly 20 million working days are lost due to migraine and the health costs caused annually by the latter represent nearly 3 billion euros. Consequently, he asks it to please specify what measures the Government plans to take with a view to providing for the reimbursement of medicines based on anti-CGRP monoclonal antibodies.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.